Department of Nuclear Medicine, Shohada e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences
Department of Radiation Oncology, Gandi Hospital, Tehran, Iran
Clin Nucl Med. 2019 Jun;44(6):483-484. doi: 10.1097/RLU.0000000000002508.
A 68-year-old man with metastatic castration-resistant prostate cancer and widespread bone metastases as well as a history of kidney transplant, underwent 5 cycles of Lu-prostate-specific membrane antigen 617 therapies in our department. Being more cautious of the radiation burden imposed on the transplanted kidney, a lower average dose of 4 GBq per cycle was administered (instead of the more routine 6.0-7.4 GBq per cycle). However, excellent response was noted and serum creatinine level of 0.8 mg/dL remained stable.
一位 68 岁患有转移性去势抵抗性前列腺癌且广泛骨转移的患者，以及肾移植病史，在我们科室接受了 5 个周期的 Lu-前列腺特异性膜抗原 617 治疗。由于更关注移植肾所承受的辐射负担，每个周期给予的平均剂量较低，为 4GBq（而不是更常规的 6.0-7.4GBq 每个周期）。然而，观察到了极好的反应，血清肌酐水平 0.8mg/dL 保持稳定。
